SCHEMBL19781245

SCHEMBL19781245

C/C(N)=C/N(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11418901 1.00
SCHEMBL23556025 0.74
SCHEMBL15831641 0.74
SCHEMBL8566704 0.73
SCHEMBL2727302 0.72
SCHEMBL16155525 0.72
SCHEMBL471929 0.72
SCHEMBL22649598 0.72
SCHEMBL15445128 0.72
SCHEMBL471928 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4230627-A2 INHIBITORS OF THE MENIN-MLL INTERACTION Vitae Pharmaceuticals, LLC (US) 2023-08-23 EP disclosed
EP-3828191-A2 NOVEL GALACTOSIDE INHIBITOR OF GALECTINS Galecto Biotech AB (DK) 2021-06-02 EP disclosed
EP-3250581-B1 ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS GALECTO BIOTECH AB (DK) 2021-01-20 EP disclosed
WO-2020078808-A1 GALACTOSIDE INHIBITOR OF GALECTINS GALECTO BIOTECH AB (DK) 2020-04-23 WO disclosed
WO-2019217757-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE DESIGN THERAPEUTICS INC. (US) 2019-11-14 WO disclosed
EP-3492484-A1 NOVEL GALACTOSIDE INHIBITOR OF GALECTINS Galecto Biotech AB (DK) 2019-06-05 EP disclosed
EP-3099687-B1 MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-07-04 EP disclosed
WO-2018011094-A1 ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS GALECTO BIOTECH AB (DK) 2018-01-18 WO disclosed